Literature DB >> 11756779

Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm.

Philipp Ströbel1, Andreas Zettl, Zhou Ren, Petr Starostik, Hubertus Riedmiller, Stephan Störkel, Hans Konrad Müller-Hermelink, Alexander Marx.   

Abstract

We describe the morphology and comparative genomic hybridization findings in a tumor for which we propose the term "spiradenocylindroma" of the kidney. The tumor arose in the wall of a renal cyst in an otherwise healthy male patient who had a favorable clinical course after nephrectomy. Tumor cells formed either large nodules exhibiting a solid or trabecular architecture with conspicuous perivascular spaces or cylindromatous small tumor cell islands arranged in a jigsaw pattern. Focally, there were interspersed tubular structures and tumor cell rosettes with central deposits of periodic acid-Schiff-positive material. A minor tumor component showed epidermoid differentiation. The tumor cells were strongly positive for cytokeratins 5/6, high molecular weight cytokeratins 34betaE12 and AE1/3, and E-cadherin, but only weakly positive for cytokeratins 7, 8, 18, 19, and epithelial membrane antigen. Focal reactivity for actin, vimentin, and S-100 protein or lysozyme and alpha 1 -antichymotrypsin within tubular and cylindromatous areas suggested myoepithelial and apocrine differentiation, respectively. By comparative genomic hybridization, the only abnormality was loss of the long arm of chromosome 16 and gain of genetic material on the short arm of chromosome 16, suggesting isochromosome i(16p). This finding is unique among renal neoplasms and implies loss of heterozygosity at 16q12-13 of the CYLD1 gene that is critically involved in the oncogenesis of familial cylindromatosis and some sporadic spiradenocylindromas. We conclude that somatic mutation of the CYLD1 gene outside the skin can have a role in the oncogenesis of tumors with cylindromatous features.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11756779     DOI: 10.1097/00000478-200201000-00016

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

Review 1.  Deubiquitinating enzymes as novel anticancer targets.

Authors:  Benjamin Nicholson; Jeffrey G Marblestone; Tauseef R Butt; Michael R Mattern
Journal:  Future Oncol       Date:  2007-04       Impact factor: 3.404

Review 2.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

3.  miR-181d regulates human dendritic cell maturation through NF-κB pathway.

Authors:  Xian Wei Su; Gang Lu; Chi Kwan Leung; Qiang Liu; Yi Li; Kam Sze Tsang; Shi Dou Zhao; Danny Tat Ming Chan; Hsiang Fu Kung; Wai Sang Poon
Journal:  Cell Prolif       Date:  2017-07-21       Impact factor: 6.831

4.  Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors.

Authors:  Yingai Jane Jin; Sally Wang; Joshua Cho; M Angelica Selim; Tim Wright; George Mosialos; Jennifer Y Zhang
Journal:  JCI Insight       Date:  2016-07-21

5.  Copy number variation of ubiquitin- specific proteases genes in blood leukocytes and colorectal cancer.

Authors:  Tian Tian; Haoran Bi; Yupeng Liu; Guangxiao Li; Yiwei Zhang; Liming Cao; Fulan Hu; Yashuang Zhao; Huiping Yuan
Journal:  Cancer Biol Ther       Date:  2020-05-04       Impact factor: 4.742

6.  CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.

Authors:  Paula Miliani de Marval; Shazia Lutfeali; Jane Y Jin; Benjamin Leshin; M Angelica Selim; Jennifer Y Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-08

7.  A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma.

Authors:  F Hunstig; S Schulz; I Nieten; U Froster; C Boltze; S Schliemann; A Hochhaus; P La Rosée
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-11       Impact factor: 4.553

Review 8.  Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.

Authors:  Patrick W Blake; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

9.  CYLD downregulation is correlated with tumor development in patients with hepatocellular carcinoma.

Authors:  Hiroki Kinoshita; Hirohisa Okabe; Toru Beppu; Akira Chikamoto; Hiromitsu Hayashi; Katsunori Imai; Kosuke Mima; Shigeki Nakagawa; Naomi Yokoyama; Takatoshi Ishiko; Satoru Shinriki; Hirofumi Jono; Yukio Ando; Hideo Baba
Journal:  Mol Clin Oncol       Date:  2013-01-14

10.  Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.

Authors:  L M Saleh; W Wang; S E M Herman; N S Saba; V Anastas; E Barber; M Corrigan-Cummins; M Farooqui; C Sun; S M Sarasua; Z Zhao; N K Abousamra; O Elbaz; H A Abdelghaffar; A Wiestner; K R Calvo
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.